HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.

Abstract
Children with hyperlipidemia secondary to renal disease develop premature atherosclerosis and glomerulosclerosis. The aims of this pilot study were to find the dosage and short-term efficacy of simvastatin and potential adverse events in children with chronic kidney diseases. This was a random, double-blind, placebo-controlled, cross-over clinical trial performed on children with hyperlipidemia secondary to kidney disorders. After being placed on a diet for 3 months, patients were randomly placed in one of two balanced group blocks and treated with diet plus placebo or simvastatin at doses of 5 mg for children weighing 30 kg or less and 10 mg for children weighing over 30 kg, for 1 month, and then doubled for two more months. After this treatment, patients were placed on a diet for a 3-month washout period. During the last trial phase, patients previously treated with simvastatin were administered a placebo, and vice versa. A total of 25 patients with ages ranging from 4 years to 17 years were included in the study. A significant decrease in the levels of serum cholesterol (26.4%), low-density lipoprotein (LDL) (35.4%) and triglycerides (23.1%) was noted during the study, primarily during the simvastatin treatments, in which case cholesterol, LDL and triglycerides decreased by 23.3%, 33.7% and 21%, respectively. High-density lipoprotein (HDL) levels increased moderately (10.7%) during the study but without differences during simvastatin treatment. No differences were found across groups with respect to adverse events. In the short-term the combination of diet and simvastatin was effective in lowering hyperlipidemia in children with renal disorders.
AuthorsSilvestre García-de-la-Puente, José Luis Arredondo-García, Pedro Gutiérrez-Castrellón, Aurora Bojorquez-Ochoa, Edith Reyna Maya, María Del Pilar Pérez-Martínez
JournalPediatric nephrology (Berlin, Germany) (Pediatr Nephrol) Vol. 24 Issue 6 Pg. 1205-10 (Jun 2009) ISSN: 1432-198X [Electronic] Germany
PMID19238452 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hypolipidemic Agents
  • Triglycerides
  • Cholesterol
  • Simvastatin
Topics
  • Child
  • Child, Preschool
  • Cholesterol (blood)
  • Cholesterol, HDL (blood)
  • Cholesterol, LDL (blood)
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Humans
  • Hyperlipidemias (complications, drug therapy)
  • Hypolipidemic Agents (adverse effects, therapeutic use)
  • Kidney Diseases (drug therapy)
  • Pilot Projects
  • Simvastatin (adverse effects, therapeutic use)
  • Time Factors
  • Treatment Outcome
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: